SynthesisClinical cardiology2019
Transcatheter aortic valve replacement in patients with pure native aortic valve regurgitation: A systematic review and meta-analysis.
Synthesis in Clinical cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Dedicated Versus Conventional Devices in Patients With Pure Native Aortic Regurgitation: A Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2025Pooled it
- Single arm meta-analysis of the J-Valve system for aortic regurgitation in Chinese populations.Frontiers in cardiovascular medicine · 2025Pooled it
- Predictors of Permanent Pacemaker Implantation in Patients Undergoing Transcatheter Aortic Valve Replacement - A Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2021Pooled it
- Transcatheter aortic valve replacement in patients with pure native aortic valve regurgitation: A systematic review and meta-analysis.Clinical cardiology · 2019Pooled it
- First-in-human TAVR With Navitor Self-expanding Intra-annular Valve in LVAD-Associated Aortic Regurgitation.Journal of the Society for Cardiovascular Angiography & Interventions · 2025Article
- Structural Heart Interventions in Patients with Left Ventricular Assist Devices.Reviews in cardiovascular medicine · 2025Review
- Cardiac Computed Tomography Angiography Anatomical Characterization of Patients Screened for a Dedicated Transfemoral Transcatheter Valve System for Primary Aortic Regurgitation.Structural heart : the journal of the Heart Team · 2023Article
- Transcatheter valvular therapies in patients with left ventricular assist devices.Frontiers in cardiovascular medicine · 2023Review
- A study on correlation between preprocedural CT indexes and procedural success rate of transfemoral transcatheter aortic valve replacement with different self-expanding valves (VitaFlow or VenusA-Valve) in patients with pure native aortic regurgitation.Annals of translational medicine · 2022Article
- Transcatheter Aortic Valve Replacement Programs: Clinical Outcomes and Developments.Journal of the American Heart Association · 2020Review
- Comment on "Transcatheter aortic valve replacement in patients with pure native aortic valve regurgitation: A systematic review and meta-analysis".Clinical cardiology · 2019Article
- TAVI for aortic regurgitation using dedicated devices. A systematic review.REC, interventional cardiologyArticle
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review and meta-analysis sought to summarize the available evidence on the use of transcatheter aortic valve replacement (TAVR) in patients with Native Aortic Valve Regurgitation (NAVR) and compare outcomes between first and second generation valves. Owing to the improvements in transcatheter heart valve design and procedural success, TAVR has become increasingly performed in broader aortic valve pathologies. We searched Medline, Embase, Cochrane, and Scopus databases from 2007 to 2018 and performed a systematic review on reports with at least 10 patients with aortic valve regurgitation undergoing TAVR procedure. The main outcome of interest was all-cause mortality at 30 days. A total of 638 patients across 12 studies were included. Mean age ranged from 68 to 84. Society of Thoracic Surgeons score ranged from 5.4% to 13.1% and Logistic EuroSCORE ranged from 18.2% to 33%. The incidence rate of all-cause mortality at 30 days was found to be 11% (95% CI 7%-16%; I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.